Drug-drug Interaction Study With ASP1941 and Glimepiride
Sponsor
Astellas Pharma Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT01302158
Collaborator
(none)
52
1
4
13.1
Study Details
Study Description
Brief Summary
A study to investigate the effect of ASP1941 on the pharmacokinetics and safety of glimepiride (Part A) and to investigate the effect of glimepiride on the pharmacokinetics, safety and pharmacodynamics of ASP1941 (Part B).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
Study includes two parts. Part A is to investigate the effect of multiple oral doses of ASP1941 on the pharmacokinetics of glimepiride, and Part B is to investigate the effect of multiple oral doses of glimepiride on the pharmacokinetics of ASP1941.
Study Design
Study Type:
Interventional
Actual Enrollment
:
52 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa
Study Start Date
:
Dec 1, 2009
Actual Primary Completion Date
:
Apr 1, 2010
Actual Study Completion Date
:
Apr 1, 2010
Outcome Measures
Primary Outcome Measures
- Effect of multiple doses of ASP1941 on the Pharmacokinetics of glimepiride [14 days]
Secondary Outcome Measures
- Effect of multiple doses of glimepiride on the Pharmacokinetics of ASP1941 [14 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- BMI between 18.5 and 30 kg/m2, inclusive
Exclusion Criteria:
-
Any of the liver function tests above the upper limit of normal
-
Pulse <40 or >90 bpm; Systolic Blood Pressure >140 mmHg; Diastolic Blood Pressure > 90 mmHg
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Groningen | Netherlands | 9470 AE |
Sponsors and Collaborators
- Astellas Pharma Inc
Investigators
- Study Director: Use Central Contact, Astellas Pharma Europe B.V.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT01302158
Other Study ID Numbers:
- 1941-CL-0059
- 2009-013172-50
First Posted:
Feb 23, 2011
Last Update Posted:
Feb 23, 2011
Last Verified:
Feb 1, 2011
Keywords provided by ,
,
Additional relevant MeSH terms: